IP Library Granted Patent US 9,849,133
Granted Patent B2
US 9,849,133 · App. 14/307,773 · Granted Dec 26, 2017

Pharmaceutical formulations of xanthine or xanthine derivatives, and their use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,849,133
App. No.
14/307,773
Granted
Dec 26, 2017
Kind
B2
Abstract

The present invention relates to pharmaceutical formulations comprising xanthine or xanthine derivatives, kits thereof, and methods for treating fibrotic diseases by local administration.

Claims (12)

1. A method for treating Peyronie's disease in a subject in need thereof, comprising injecting into at least one of the corpus cavernosa of the penis of the subject a pharmaceutical formulation consisting essentially of a therapeutic effective amount of pentoxifylline or a pharmaceutically acceptable salt thereof, wherein the formulation is used as a mono therapy for treating Peyronie's disease.

2. The method of claim 1 , wherein the pharmaceutical formulation has a pH between 5.5 and 6.

3. The method of claim 1 , wherein the therapeutically effective amount is between 4 mg and 20 mg per day.

4. The method of claim 1 , wherein the pharmaceutical formulation is injected at the base of the penis about 2 cm from where the penis attaches to the abdomen.

5. The method of claim 1 , wherein at least one symptom of Peyronie's disease is improved.

6. The method of claim 5 , wherein the at least one symptom is pain.

7. The method of claim 5 , wherein the at least one symptom is penile curvature.

8. The method of claim 5 , wherein the at least one symptom is erectile dysfunction.

9. The method of claim 3 , wherein at least one symptom of Peyronie's disease is improved.

10. The method of claim 9 , wherein the at least one symptom is pain.

11. The method of claim 9 , wherein the at least one symptom is penile curvature.

12. The method of claim 9 , wherein the at least one symptom is erectile dysfunction.

Assignments (10)
SECURITY INTEREST Recorded Sep 26, 2025
From: HARROW, INC.; HARROW IP, LLC
To: FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 072384/0781 →
RELEASE OF SECURITY INTEREST Recorded Sep 18, 2025
From: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
To: HARROW IP, LLC
Reel/Frame 072299/0911 →
PATENT SECURITY AGREEMENT Recorded Mar 30, 2023
From: HARROW IP, LLC
To: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 063205/0708 →
RELEASE OF SECURITY INTEREST Recorded May 7, 2021
From: SWK FUNDING LLC
To: HARROW IP, LLC
Reel/Frame 056174/0332 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2019
From: ETON PHARMACEUTICALS, INC.
To: HARROW IP, LLC
Reel/Frame 049402/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2017
From: IMPRIMIS PHARMACEUTICALS, INC.
To: ETON PHARMACEUTICALS, INC.
Reel/Frame 043120/0957 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 19, 2017
From: IMPRIMIS PHARMACEUTICALS, INC.
To: SWK FUNDING LLC, AS COLLATERAL AGENT
Reel/Frame 043258/0581 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY COLLATERAL AT REEL/FRAME NO. 35923/0749 Recorded Jul 19, 2017
From: IMMY FUNDING LLC
To: IMPRIMIS PHARMACEUTICALS, INC.
Reel/Frame 043259/0434 →
SECURITY INTEREST Recorded Jun 16, 2015
From: IMPRIMIS PHARMACEUTICALS, INC.
To: IMMY FUNDING LLC
Reel/Frame 035923/0749 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2014
From: BUDERER, MATTHEW J.
To: IMPRIMIS PHARMACEUTICALS, INC.
Reel/Frame 033630/0592 →